Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Cost of Revenue: 2016-2024

Historic Cost of Revenue for UroGen Pharma (URGN) over the last 8 years, with Dec 2024 value amounting to $8.9 million.

  • UroGen Pharma's Cost of Revenue rose 33.63% to $3.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.6 million, marking a year-over-year increase of 33.73%. This contributed to the annual value of $8.9 million for FY2024, which is 5.13% down from last year.
  • As of FY2024, UroGen Pharma's Cost of Revenue stood at $8.9 million, which was down 5.13% from $9.4 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Cost of Revenue registered a high of $9.4 million during FY2023, and its lowest value of $1.0 million during FY2020.
  • For the 3-year period, UroGen Pharma's Cost of Revenue averaged around $8.6 million, with its median value being $8.9 million (2024).
  • In the last 5 years, UroGen Pharma's Cost of Revenue skyrocketed by 411.10% in 2021 and then dropped by 5.13% in 2024.
  • UroGen Pharma's Cost of Revenue (Yearly) stood at $1.0 million in 2020, then soared by 411.10% to $5.2 million in 2021, then soared by 48.42% to $7.7 million in 2022, then grew by 22.30% to $9.4 million in 2023, then fell by 5.13% to $8.9 million in 2024.